EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 52017XC1201(03)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
OJ C 410, 1.12.2017, p. 1–4
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
1.12.2017 |
EN |
Official Journal of the European Union |
C 410/1 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2017 to 31 October 2017
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))
(2017/C 410/01)
— |
Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted |
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
3.10.2017 |
Beromun |
Boehringer Ingelheim International GmbH Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland |
EU/1/99/097 |
5.10.2017 |
3.10.2017 |
Lantus |
Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Deutschland |
EU/1/00/134 |
5.10.2017 |
3.10.2017 |
Ristaben |
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom |
EU/1/10/621 |
5.10.2017 |
3.10.2017 |
Synflorix |
GlaxoSmithKline Biologicals S.A. rue de l’Institut 89, 1330 Rixensart, Belgique |
EU/1/09/508 |
5.10.2017 |
3.10.2017 |
Toujeo |
Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Deutschland |
EU/1/00/133 |
5.10.2017 |
3.10.2017 |
Zoely |
Teva B.V. Swensweg 5, 2031 GA Haarlem, Nederland |
EU/1/11/690 |
5.10.2017 |
4.10.2017 |
Empliciti |
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom |
EU/1/16/1088 |
6.10.2017 |
4.10.2017 |
Twinrix Adult |
GlaxoSmithKline Biologicals S.A. rue de l’Institut 89, 1330 Rixensart, Belgique |
EU/1/96/020 |
6.10.2017 |
9.10.2017 |
Ambirix |
GlaxoSmithKline Biologicals S.A. rue de l’Institut 89, 1330 Rixensart, Belgique |
EU/1/02/224 |
11.10.2017 |
9.10.2017 |
Erivedge |
Roche Registration Limited 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom |
EU/1/13/848 |
11.10.2017 |
13.10.2017 |
Amlodipine/Valsartan Mylan |
Mylan S.A.S 117 allée des Parcs, 69800 Saint Priest, France |
EU/1/16/1092 |
17.10.2017 |
13.10.2017 |
Emtricitabine/Tenofovir disoproxil Zentiva |
Zentiva, k.s. U Kabelovny 130, 102 37 Praha 10, Česká republika |
EU/1/16/1148 |
17.10.2017 |
13.10.2017 |
JETREA |
ThromboGenics NV Gaston Geenslaan 1, 3001 Leuven, België |
EU/1/13/819 |
17.10.2017 |
13.10.2017 |
Twinrix Paediatric |
GlaxoSmithKline Biologicals S.A. rue de l’Institut 89, 1330 Rixensart, Belgique |
EU/1/97/029 |
17.10.2017 |
13.10.2017 |
Ulunar Breezhaler |
Novartis Europharm Limited Frimley Business Park, Camberley GU16 7SR, United Kingdom |
EU/1/14/917 |
17.10.2017 |
13.10.2017 |
Wakix |
Bioprojet Pharma 9 rue Rameau, 75002 Paris, France |
EU/1/15/1068 |
17.10.2017 |
19.10.2017 |
Emend |
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom |
EU/1/03/262 |
24.10.2017 |
19.10.2017 |
Firazyr |
Shire Orphan Therapies GmbH Friedrichstraße 149, 10117 Berlin, Deutschland |
EU/1/08/461 |
23.10.2017 |
19.10.2017 |
Humalog |
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht, Nederland |
EU/1/96/007 |
23.10.2017 |
19.10.2017 |
Mozobil |
Genzyme Europe B.V. Gooimeer 10, 1411 DD Naarden, Nederland |
EU/1/09/537 |
23.10.2017 |
19.10.2017 |
Opdivo |
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom |
EU/1/15/1014 |
23.10.2017 |
19.10.2017 |
Pradaxa |
Boehringer Ingelheim International GmbH Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland |
EU/1/08/442 |
23.10.2017 |
19.10.2017 |
Revestive |
Shire Pharmaceuticals Ireland Limited 5 Riverwalk, Citywest Business Campus, Dublin 24, Ireland |
EU/1/12/787 |
23.10.2017 |
19.10.2017 |
Stribild |
Gilead Sciences International Limited Cambridge CB21 6GT, United Kingdom |
EU/1/13/830 |
23.10.2017 |
19.10.2017 |
Xarelto |
Bayer AG D-51368 Leverkusen, Deutschland |
EU/1/08/472 |
23.10.2017 |
19.10.2017 |
Yondelis |
Pharma Mar S.A. Avenida de los Reyes 1, Polígono Industrial La Mina, 28770 Colmenar Viejo, Madrid, España |
EU/1/07/417 |
23.10.2017 |
23.10.2017 |
Giotrif |
Boehringer Ingelheim International GmbH Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland |
EU/1/13/879 |
25.10.2017 |
23.10.2017 |
Instanyl |
Takeda Pharma A/S Dybendal Alle 10, 2630 Taastrup, Danmark |
EU/1/09/531 |
25.10.2017 |
23.10.2017 |
Levetiracetam Actavis Group |
Actavis Group PTC ehf. Reykjavíkurvegi 76-78, 220 Hafnarfjörður, Íceland |
EU/1/11/738 |
25.10.2017 |
23.10.2017 |
Liprolog |
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht, Nederland |
EU/1/01/195 |
25.10.2017 |
23.10.2017 |
Olanzapine Glenmark |
Glenmark Pharmaceuticals Europe Limited Laxmi House, 2B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 0BU, United Kingdom |
EU/1/09/587 |
25.10.2017 |
23.10.2017 |
Olanzapine Glenmark Europe |
Glenmark Pharmaceuticals Europe Limited Laxmi House, 2B Draycott Avenue, Kenton, Harrow, Middlesex, HA3 0BU, United Kingdom |
EU/1/09/588 |
25.10.2017 |
23.10.2017 |
Prevenar 13 |
Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom |
EU/1/09/590 |
25.10.2017 |
30.10.2017 |
Competact |
Takeda Pharma A/S Dybendal Alle 10, 2630 Taastrup, Danmark |
EU/1/06/354 |
1.11.2017 |
30.10.2017 |
Epclusa |
Gilead Sciences International Ltd Flowers Building, Granta Park, Abington, Cambridge CB21 6GT United Kingdom |
EU/1/16/1116 |
1.11.2017 |
30.10.2017 |
Firdapse |
BioMarin Europe Ltd 10 Bloomsbury Way, London WC1A 2SL, United Kingdom |
EU/1/09/601 |
1.11.2017 |
30.10.2017 |
Fortacin |
Recordati Ireland Ltd Raheens East, Ringaskiddy, Co. Cork, Ireland |
EU/1/13/881 |
1.11.2017 |
30.10.2017 |
Ibandronic Acid Teva |
Teva B.V. Swensweg 5, 2031 GA Haarlem, Nederland |
EU/1/10/642 |
2.11.2017 |
30.10.2017 |
Multaq |
Sanofi-Aventis groupe 54 rue La Boétie, 75008 Paris, France |
EU/1/09/591 |
2.11.2017 |
30.10.2017 |
Tarceva |
Roche Registration Limited 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom |
EU/1/05/311 |
1.11.2017 |
30.10.2017 |
Ultibro Breezhaler |
Novartis Europharm Limited Frimley Business Park, Camberley GU16 7SR, United Kingdom |
EU/1/13/862 |
1.11.2017 |
30.10.2017 |
Venclyxto |
AbbVie Ltd Vanwall Road, Maidenhead, SL6 4UB, United Kingdom |
EU/1/16/1138 |
1.11.2017 |
— |
Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted |
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorization |
Number of the entry in the Community Register |
Date of notification |
5.10.2017 |
Equisolon |
Le Vet B.V. Wilgenweg 7, 3421 TV Oudewater, Nederland |
EU/2/14/161 |
10.10.2017 |
10.10.2017 |
Simparica |
Zoetis Belgium S.A. rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique |
EU/2/15/191 |
12.10.2017 |
19.10.2017 |
Bovela |
Boehringer Ingelheim International GmbH Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland |
EU/2/14/176 |
23.10.2017 |
24.10.2017 |
Inflacam |
Chanelle Pharmaceuticals Manufacturing Limited Loughrea, Co. Galway, Ireland |
EU/2/11/134 |
26.10.2017 |
24.10.2017 |
Ingelvac CircoFLEX |
Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein, Deutschland |
EU/2/07/079 |
26.10.2017 |
31.10.2017 |
Pexion |
Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein, Deutschland |
EU/2/12/147 |
6.11.2017 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
European Medicines Agency |
30 Churchill Place |
Canary Wharf |
London E14 5EU |
United Kingdom |
(1) OJ L 136, 30.4.2004, p. 1.